Urovant Sciences (NASDAQ:UROV) Issues Quarterly Earnings Results

Share on StockTwits

Urovant Sciences (NASDAQ:UROV) issued its quarterly earnings results on Tuesday. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.92) by ($0.02), Morningstar.com reports.

NASDAQ UROV opened at $7.54 on Wednesday. Urovant Sciences has a 1-year low of $4.05 and a 1-year high of $14.49. The company has a debt-to-equity ratio of 0.18, a quick ratio of 8.34 and a current ratio of 8.34. The firm has a 50-day moving average of $8.24. The company has a market cap of $227.55 million and a price-to-earnings ratio of -1.70.

Several brokerages have issued reports on UROV. HC Wainwright set a $28.00 price target on Urovant Sciences and gave the stock a “buy” rating in a research note on Monday, June 24th. ValuEngine raised Urovant Sciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Zacks Investment Research lowered Urovant Sciences from a “hold” rating to a “sell” rating in a research note on Wednesday, May 22nd. Finally, JPMorgan Chase & Co. set a $24.00 target price on Urovant Sciences and gave the company a “buy” rating in a research note on Friday, June 14th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $21.63.

In related news, major shareholder Andrew Lo bought 18,204 shares of the stock in a transaction dated Wednesday, June 19th. The stock was bought at an average price of $8.32 per share, with a total value of $151,457.28. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Holdings Ltd. Dexxon bought 22,011 shares of the stock in a transaction dated Friday, June 14th. The stock was bought at an average cost of $8.06 per share, with a total value of $177,408.66. The disclosure for this purchase can be found here. In the last three months, insiders bought 167,952 shares of company stock valued at $1,330,019. 2.40% of the stock is currently owned by corporate insiders.

A number of large investors have recently made changes to their positions in UROV. Barclays PLC purchased a new position in Urovant Sciences during the 4th quarter valued at about $37,000. Marshall Wace North America L.P. purchased a new position in Urovant Sciences during the 1st quarter valued at about $49,000. Two Sigma Investments LP purchased a new position in Urovant Sciences during the 4th quarter valued at about $72,000. Northern Trust Corp increased its holdings in Urovant Sciences by 55.8% during the 2nd quarter. Northern Trust Corp now owns 17,164 shares of the company’s stock valued at $136,000 after purchasing an additional 6,144 shares during the period. Finally, Marshall Wace LLP purchased a new position in Urovant Sciences during the 1st quarter valued at about $325,000. Institutional investors own 21.91% of the company’s stock.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Read More: How does the Beige Book influence monetary policy?

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

State Board of Administration of Florida Retirement System Lowers Stock Holdings in Torchmark Co.
State Board of Administration of Florida Retirement System Lowers Stock Holdings in Torchmark Co.
Securian Asset Management Inc Grows Stock Position in Viacom, Inc.
Securian Asset Management Inc Grows Stock Position in Viacom, Inc.
Zacks: Analysts Expect Santander Consumer USA Holdings Inc  to Post $0.67 Earnings Per Share
Zacks: Analysts Expect Santander Consumer USA Holdings Inc to Post $0.67 Earnings Per Share
Dynavax Technologies Co.  Receives Average Rating of “Buy” from Analysts
Dynavax Technologies Co. Receives Average Rating of “Buy” from Analysts
Cara Therapeutics Inc  Expected to Announce Earnings of -$0.59 Per Share
Cara Therapeutics Inc Expected to Announce Earnings of -$0.59 Per Share
Essential Properties Realty Trust Inc  Receives Consensus Recommendation of “Hold” from Analysts
Essential Properties Realty Trust Inc Receives Consensus Recommendation of “Hold” from Analysts


© 2006-2019 Ticker Report